Open label, single-dose, randomized, 2-period, 2-sequence crossover bioequivalence study of pregabalin in healthy Korean male subjects

Trial Profile

Open label, single-dose, randomized, 2-period, 2-sequence crossover bioequivalence study of pregabalin in healthy Korean male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2017

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Fibromyalgia; Generalised anxiety disorder; Generalised epilepsy; Neuropathic pain; Pain; Partial epilepsies; Postherpetic neuralgia; Postoperative pain; Restless legs syndrome
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Jan 2017 New trial record
    • 27 Dec 2016 Results published in the International Journal of Clinical Pharmacology and Therapeutics
    • 27 Dec 2016 According to the results published in the International Journal of Clinical Pharmacology and Therapeutics, this study was conducted at the Clinical Trials Center of Kyung Hee University Hospital.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top